

Amendments to the Claims

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims:

Claims 1-100. **[Canceled]**

Claim 101. **[Currently Amended]** An antibody which comprises an antigen binding region and a variant Fc region, wherein said variant Fc region:

- (A) differs from a wild-type Fc region by comprising **at least** an amino acid modification at position 396, according to the EU index as in Kabat, relative to said wild-type Fc region; and
- (B) binds an FcγR with an increased affinity relative to a said wild-type Fc region.

Claim 102. **[Withdrawn]** The antibody of claim 101, wherein said variant Fc region differs from said wild-type Fc region in comprising additional amino acid modification(s) at position 210; 215; 217; 246; 250; 255; 268; 288; 290; or 419 of said wild-type Fc region.

Claim 103. **[Withdrawn]** The antibody of claim 101, wherein said variant Fc region differs from said wild-type Fc region in comprising additional amino acid modification(s) of said wild-type Fc region selected from the group consisting of: 210M; 217S; 227S; 240A; 242F; 244H; 246T; 247S; 248M; 250A; 250S; 255I; 255L; 258D; 268D; 268N; 303I; 305L; 323I; 326I; 334N; 358P; 370E; 375C; 379M; 384K; 392T; 400F; 410H; 419H; 419L; or 427A.

Claim 104. **[Withdrawn]** The antibody of claim 101, wherein said variant Fc region differs from said wild-type Fc region in comprising additional amino acid modification(s) of said wild-type Fc region selected from the group consisting of:

- (1) 221E; 270E; 308A, 311H and 402D;
 - (2) 319F and 352L;
 - (3) 288R; 307A; and 344E;
 - (4) 210M and 261N;
- and
- (5) 243L; 305I; 378D; and 404S.

Claim 105. **[Previously Presented]** The antibody of any of claims 101-104, wherein said FcγR is FcγRIIIA.

Claim 106. **[Previously Presented]** The antibody of claim 105, wherein said variant Fc region of said polypeptide has decreased affinity for FcγRIIB relative to said wild-type Fc region.

Claim 107. **[Previously Presented]** The antibody of claim 106, wherein said variant Fc region comprises amino acid modifications of said wild-type Fc region selected from the group consisting of:

- (1) 221E; 270E; 308A; 311H; 396L and 402D;
 - (2) 243L; 305I; 376D; 404S; and 396L;
 - (3) 255I and 396L;
 - (4) 370E and 396L.
 - (5) 392T and 396L;
- and
- (6) 410H and 396L.

Claim 108. **[Previously Presented]** The antibody of any of claims 101-104 wherein said wild-type Fc region is an Fc region of a human IgG Fc region.

- Claim 109. **[Previously Presented]** The antibody of claim 108, wherein said human IgG Fc region is a human IgG1, IgG2, IgG3, or IgG4 Fc region.
- Claim 110. **[Previously Presented]** The antibody of claim 108, wherein said variant Fc region of said antibody specifically binds FcγRIIIA with at least two times greater affinity than the wild-type Fc region.
- Claim 111. **[Previously Presented]** The antibody of claim 101-104, wherein said antigen binding region binds a cancer antigen or an antigen associated with an infectious disease.
- Claim 112. **[Previously Presented]** The antibody of claim 111, wherein said antibody binds a cancer antigen and mediates antibody dependent cell mediated cytotoxicity 2-fold more effectively than an antibody comprising said wild-type Fc region.
- Claim 113. **[Previously Presented]** The antibody of claim 111, wherein said antibody binds a cancer antigen and said cancer antigen is HER-2/neu, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, MUM-1, CDK4, MUC-1, N-acetylglucosaminyltransferase, p15, beta-catenin, human papillomavirus-E6, or human papillomavirus-E7.
- Claim 114-137. **[Cancelled]**
- Claim 138. **[Previously Presented]** The antibody of claim 101, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 139. **[Previously Presented]** The antibody of claim 105, wherein said amino acid modification at position 396 is a substitution of leucine at said position.

- Claim 140. **[Previously Presented]** The antibody of claim 106, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 141. **[Previously Presented]** The antibody of claim 108, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 142. **[Previously Presented]** The antibody of claim 110, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 143. **[Previously Presented]** The antibody of claim 111, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 144. **[Previously Presented]** The antibody of claim 112, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 145. **[Previously Presented]** The antibody of claim 113, wherein said amino acid modification at position 396 is a substitution of leucine at said position.
- Claim 146. **[Previously Presented]** The antibody of claim 114, wherein said amino acid modification at position 396 is a substitution of leucine at said position.